Defining Success in Ablation: Challenges in Trial Design and Comparative Outcomes in the Era of PFA

Atrial fibrillation ablation trials have significantly evolved over the past 3 decades, especially recently with the introduction of pulsed field ablation. Efficacy endpoint definitions are inconsistent among clinical trials, leaving the readers (ie, physicians, patients, payers, and regulators) to determine which values are most meaningful and how to compare results across various technologies. This review highlights differences in study design, atrial arrhythmia monitoring methods, and endpoint definitions of key pulsed field ablation trials and discusses the challenges of making cross-trial comparisons. Ultimately, a coordinated effort by physician-researchers, in collaboration with industry partners and regulatory agencies, could establish consensus-driven benchmarks for clinical success, recurrence thresholds, and quality-of-life measures. Such harmonization would enhance the reliability of cross-trial comparisons and support faster, better informed decision-making in both clinical and policy settings.